Tredje AP fonden Has $9.63 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Tredje AP fonden decreased its stake in Zoetis Inc. (NYSE:ZTS) by 32.1% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 55,572 shares of the company’s stock after selling 26,323 shares during the period. Tredje AP fonden’s holdings in Zoetis were worth $9,634,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Webster Bank N. A. raised its position in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the period. Neo Ivy Capital Management bought a new stake in Zoetis in the fourth quarter valued at approximately $40,000. LRI Investments LLC bought a new stake in Zoetis in the first quarter valued at approximately $43,000. Hazlett Burt & Watson Inc. raised its holdings in Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares during the period. Finally, Central Valley Advisors LLC bought a new position in shares of Zoetis during the second quarter worth $49,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.8 %

NYSE:ZTS opened at $195.74 on Wednesday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market cap of $88.68 billion, a P/E ratio of 37.71, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The business has a 50 day moving average price of $183.65 and a two-hundred day moving average price of $174.15.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the prior year, the company posted $1.41 earnings per share. The firm’s revenue was up 8.3% on a year-over-year basis. As a group, analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on ZTS shares. Stifel Nicolaus restated a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a research report on Tuesday, August 27th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Piper Sandler boosted their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.